短期新辅助内分泌治疗对前列腺癌组织中MUC1表达的影响  

Impact of short-term neoadjuvant hormone therapy on MUC1 expression in prostate carcinoma

作　　者：崔志刚[1] 刘淳[1] 刘刚[1] 岳明[1] 梁会泽[2] 许永杰[2] 

机构地区：[1]解放军第306医院泌尿外科,北京100101 [2]解放军第306医院超声科,北京100101

出　　处：《中国临床研究》2015年第6期698-701,共4页Chinese Journal of Clinical Research

摘　　要：目的探讨短期新辅助内分泌治疗（NHT）前后前列腺癌组织MUC1表达水平的变化及其临床意义。方法2004年1月至2011年1月21例前列腺癌患者纳入本研究,患者经B超引导下行前列腺穿刺活检病理检查确诊为前列腺癌后先行NHT 3~9个月,然后行前列腺癌根治性切除术。NHT采用促性腺激素释放激素激动剂联合抗雄激素药物的最大雄激素阻断治疗。取NHT前穿刺活检标本及NHT后的前列腺癌根治性切除术后大体标本采用免疫组织化学方法检测前列腺癌组织内MUC1表达水平;检测血清总前列腺特异抗原（t PSA）水平;前列腺癌组织分级采用Gleason评分系统;NHT后MUC1表达与血清t PSA水平及Gleason评分的相关性采用Spearman＇s相关分析。结果 NHT治疗前癌组织中MUC1表达弱阳性,染色强度为（1.52±0.59）;NHT治疗后MUC1表达增强,染色强度为（2.27±0.88）,NHT后MUC1表达高于NHT前,差异有统计学意义（P〈0.05）;治疗前后前列腺癌Gleason评分分别为（6.5±0.3）、（6.1±0.8）,差异无统计学意义（P〉0.05）;NHT治疗前后血t PSA水平分别为（80.81±22.26）ng/ml、（4.11±1.72）ng/ml,差异有统计学意义（P〈0.01）。NHT治疗后前列腺癌组织中MUC1表达与前列腺癌Gleason评分无相关性（r=0.075,P〉0.05）,与血清t PSA水平呈正相关（r=0.507,P〈0.05）。结论短期NHT可使前列腺癌细胞内MUC1表达上调,针对MUC1的辅助治疗有可能提高短期NHT的效果。Objective To investigate the change of expression levels of Tat-conjugated N-terminal region of mucin antigen1（ MUC1） in prostate cancer tissues before and after short-term neoadjuvant hormone therapy（ NHT） and its clinical significance. Methods Twenty-one patients diagnosed as prostate carcinoma between January 2004 and January 2011 were enrolled in present study. After definitely diagnosed as prostate carcinoma with needle biopsy under the guide of B ultrasound,the radical prostatectomy was performed following NHT for 3 to 9 months. The maximum androgen-deprivation therapy including gonadotropin hormone-releasing hormone agonists plus anti-androgen drugs were used for NHT. The expression levels of MUC1 in prostate cancer tissues of needle biopsy specimens before NHT and gross specimens after radical prostatectomy following NHT were detected with immunohistochemistry. The levels of serum total prostate specific antigen（t PSA） were detected. The Gleason score system was adopted for pathological grading of prostate cancer tissue. The Spearman correlation analysis was used for investigating the relativity of the MUC1 expression and the serum t PSA level or the Gleason score after NHT. Results The MUC1 expression in cancer tissues before NHT presented weakly positive with（1. 52 ± 0. 59） staining power;the MUC1 expression in cancer tissues after NHT strengthened with（2. 27 ± 0. 88） staining power;the MUC1 expression in cancer tissues after NHT was significantly higher than that before NHT（ P〈0. 05）. Compared with the Gleason score before NHT,the Gleason score after NHT remained unchanged[（6. 5 ± 0. 3） vs（6. 1 ± 0. 8）,P〈0. 05]. There was significant difference in serum t PSA levels before and after NHT [（ 80. 81 ± 22. 26） ng / ml vs（4. 11 ± 1. 72）ng/ml,P〈0. 01]. The MUC1 expression in cancer tissues after NHT was not correlated with Gleason score of prostate cancer（ r = 0. 075,P〉0. 05） but was positively correlated with serum t PSA level（ r = 0. 507,P〈0. 05

关 键 词：前列腺肿瘤 新辅助内分泌治疗 MUC1粘蛋白 总前列腺特异抗原 

分 类 号：R737.25[医药卫生—肿瘤]